PKCi & mTOR Inhibition With Auranofin+Sirolimus for Squamous Cell Lung Cancer

Inclusion Criteria:

Histologic or cytologic confirmation of stage IV NSCLC with squamous features; NOTE: Mixed histology allowed if all components consistent with NSCLC; patients whose tumors have squamous cell histology/features are eligible Patients must have received one course of chemotherapy consisting of at least four cycles of a platinum doublet with no evidence of disease progression at study entry

Prior radiation therapy is permitted as long as:

* Recovered from the toxic effects of radiation treatment before study entry, except for alopecia Absolute neutrophil count (ANC) >= 1500 uL Platelets (PLT) >= 100,000 uL Hemoglobin (Hgb) >= 9 g/dL Total bilirubin =< 1.5 x upper limit of normal (ULN) or direct bilirubin =< ULN Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) and serum glutamic pyruvic transaminase (SGPT) (alanine aminotransferase [ALT]) =< 3 x ULN or SGOT (AST) and SGPT (ALT) =< 5 x ULN is acceptable if liver has tumor involvement Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, 2 Negative serum pregnancy test done =< 7 days prior to registration, for women of childbearing potential only Ability to provide informed consent Life expectancy >= 12 weeks Willing to return to Mayo Clinic enrolling institution for follow-up Willing to provide tissue and blood samples for correlative research purposes

Exclusion Criteria:

Any of the following because this study involves an agent that has known genotoxic, mutagenic and teratogenic effects:

• Pregnant women
• Nursing women
• Men or women of childbearing potential who are unwilling to employ adequate contraception Symptomatic, untreated, or uncontrolled central nervous system (CNS) metastases or seizure disorder; NOTE: Patients with treated CNS metastases without evidence of progression and without uncontrolled symptoms or need for steroids may enroll Human immunodeficiency virus (HIV)-positive patients receiving combination anti-retroviral therapy are excluded because of possible pharmacokinetic interactions with oral investigational agents Unwilling or unable to, comply with the protocol

Any of the following prior therapies:

• Radiation to >= 25% of bone marrow
• Major surgery (i.e., laparotomy), open biopsy, or significant traumatic injury =< 4 weeks prior to registration; minor surgery =< 2 weeks prior to registration; insertion of a vascular access device is not considered major or minor surgery in this regard Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements

Any of the following concurrent severe and/or uncontrolled medical conditions:

• Hypertension, labile hypertension, or history of poor compliance with antihypertensive medication
• Angina pectoris
• History of congestive heart failure =< 84 days (3 months), unless ejection fraction > 40%
• Myocardial infarction =< 168 days (6 months) prior to registration
• Cardiac arrhythmia
• Poorly controlled diabetes
• Interstitial pneumonia or extensive and symptomatic interstitial fibrosis of the lung
• Active or recent history of hemoptysis; if hemoptysis has resolved with measures such as palliative radiation therapy (e.g. 3000 cGy over 10 fractions), arteriographic embolization or endobronchial interventions (e.g. photodynamic therapy, brachytherapy), etc. for > 14 days, patients may be considered for participation in this study
• > grade 2 hypertriglyceridemia
• >/= grade 2 hypercholesterolemia Use of St. John's Wort because of its effects on hepatic drug metabolism Other active malignancy =< 5 years prior to registration; EXCEPTIONS: Non-melanoma skin cancer, localized prostate cancer, or carcinoma-in-situ of the cervix; NOTE: If there is a history or prior malignancy, patient must not be receiving other cytotoxic or molecularly targeted therapeutics treatment for their cancer; patients receiving certain hormonal manipulations as part of their treatment may be allowed to continue at the discretion of the Principal Investigator (PI) (e.g. luteinizing hormone-releasing hormone [LHRH] analogs for prostate cancer); concurrent endocrine therapy for breast cancer will not be permitted Unable to discontinue use of potent cytochrome P450 3A4 (CYP3A4) inhibitors/inducers